@shravanrayhaan@ariaradnia Huh? Insiders buy when they think the stock has gotten too cheap. To the point where it's clearly undervalued. They do give a damn about free money. They don't appear to think it's an obvious buy yet
@PeterBerezinBCA It's a reasonable theory. Who do you think benefits most then, in this case. The suppliers like $NVDA and $AMD? as well as the end-user of course
@WillBiddy_ Even many other SaaS names have better moat than $ADBE when you consider AI threat. I own just 4-5 SaaS companies and $ADBE is probably the most questionable and at-risk. I do own it but they have some questions they need to answer for the market
@joecarlsonshow Well these companies are in uncharted territory in terms of the massive capex / infrastructure buildout. I still own some $META and $GOOGL and $MSFT but I think the clearer play is the companies that receive all this capex money. I'm up 5x on $AMD. $NVDA looks good here now. Etc
@intellivisi0x@EricBalchunas No, they do not. They can also go to zero if the underlying stock loses 33% in a day. (if 3x levered). Don't buy this junk. Just buy stocks or Call options
Approaching 20% gain for the day on this trade :)
Just a small, fun position. Willing to lose it all
I wouldn't even know about this stock if I hadn't been monitoring recent insider buying
A bit more insider buying on $MYO yesterday
Micro-cap medical robotics company
This is high-risk, high-reward. Fidelity made me agree to a Penny Stock disclosure just to trade this. But I entered a small position last week. Not financial advice.
@AlphaOwlTrading If $HIMS core business reaccelerates then the stock will too. HIMS board member David Wells bought $1.17 million in stock on May 26, so maybe he's seeing this as well
@hypergrowth102 Peptides could be a massive catalyst for $HIMS. Board member David Wells bought $1.17 million in HIMS stock on May 26, so maybe he's seeing this as well